Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.
Tag Archive for: Skyhawk Therapeutics
Three European biopharma firms are coming together to create one company with a mission to combat antimicrobial resistance (AMR). The new company, Aurobac Therapeutics SAS, was founded by Germany’s Boehringer Ingelheim and Evotec SE, along with France’s bioMérieux.
